Skip to main content

Advertisement

Table 1 Transition probabilities employed in the model

From: Cost-effectiveness analysis of treatment with peginterferon-alfa-2a versus peginterferon-alfa-2b for patients with chronic hepatitis C under the public payer perspective in Brazil

Health status Transition Probability (annual)
From To Rate
Chronic hepatitis C Compensated cirrhosis [25, 26] 0.073
Compensated cirrhosis Decompensated cirrhosis [27, 28] 0.039
  Hepatocellular carcinoma [25, 29, 30] 0.014
Decompensated cirrhosis Hepatocellular carcinoma [25, 27, 28] 0.014
  Liver transplant (1st year) [31] 0.031
  Death [24, 25, 29] 0.129
Hepatocellular carcinoma Death [25] 0.427
Liver transplant Death (1st year) [24, 29, 3234] 0.210
Liver transplant Death (> 1 year) [24, 2932] 0.057